Literature DB >> 12808056

Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.

Joe A Chorny1, Ronald J Barr, Ainura Kyshtoobayeva, James Jakowatz, Richard J Reed.   

Abstract

Minimal deviation melanoma is a controversial entity encompassing a heterogeneous group of lesions cytologically in the spectrum between recognized subtypes of nevi and conventional "primary configuration" melanomas and reported to have a better prognosis than the latter. To evaluate the distinctiveness of minimal deviation melanoma, Ki-67 proliferation rates and p53 expression in minimal deviation melanomas were compared with those in compound nevi, Spitz nevi, and vertical growth phase superficial spreading malignant melanoma. Twelve examples of each lesion were immunostained with antibodies to the Ki-67 and p53 proteins and evaluated by a pathologist who was blind to the diagnoses. The mean Ki-67 (MIB-1) proliferation rates for the compound nevi, Spitz nevi, minimal deviation melanomas, and superficial spreading malignant melanomas were 0, 3%, 13%, and 25%, respectively. The mean Ki-67 proliferation rate was statistically greater in the minimal deviation melanomas than in the compound nevi or the Spitz nevi (P <.05), but the proliferation rates in the two melanoma subtypes were not statistically significant (P =.08). The mean p53 values for these lesions were 0, 9%, 9%, and 26%, respectively; the latter two were statistically different (P <.01). Based on these Ki-67 and p53 immunophenotypes, minimal deviation melanoma may represent a distinct entity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12808056     DOI: 10.1097/01.MP.0000072747.08404.38

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

1.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

Review 2.  Unusual histologic and clinical variants of melanoma: implications for therapy.

Authors:  A Neil Crowson; Cynthia Magro; Martin C Mihm
Journal:  Curr Treat Options Oncol       Date:  2006-05

Review 3.  Unusual histologic and clinical variants of melanoma: implications for therapy.

Authors:  A Neil Crowson; Cynthia Magro; Martin C Mihm
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

Review 4.  Melanocytic nevi simulant of melanoma with medicolegal relevance.

Authors:  Guido Massi
Journal:  Virchows Arch       Date:  2007-07-26       Impact factor: 4.064

5.  Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression.

Authors:  G E Piérard
Journal:  ISRN Dermatol       Date:  2012-01-11

6.  ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression.

Authors:  Jaskaren S Kohli; Hira Mir; Afsheen Wasif; Heung Chong; Victoria Akhras; Rajiv Kumar; Eduardo Nagore; Dorothy C Bennett
Journal:  Oncotarget       Date:  2017-11-01

Review 7.  Current state of melanoma diagnosis and treatment.

Authors:  Lauren E Davis; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2019-08-01       Impact factor: 4.742

8.  A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma.

Authors:  Arnaud Uguen; Matthieu Talagas; Sebastian Costa; Sandrine Duigou; Stéphanie Bouvier; Marc De Braekeleer; Pascale Marcorelles
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.